#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=The Flavivirus genus of the family Flaviviridae includes several arthropod-borne human pathogens that may cause a spectrum of clinical syndromes ranging from a mild febrile illness to severe hemorrhagic fever or neuroinvasive disease .
3-1	17-20	The	abstract[4]	new[4]	_	_
3-2	21-31	Flavivirus	plant|abstract[4]	new|new[4]	coref	17-20
3-3	32-37	genus	abstract[4]	new[4]	_	_
3-4	38-40	of	abstract[4]	new[4]	_	_
3-5	41-44	the	abstract[4]|animal[6]	new[4]|new[6]	_	_
3-6	45-51	family	abstract[4]|person|animal[6]	new[4]|new|new[6]	_	_
3-7	52-64	Flaviviridae	abstract[4]|animal[6]	new[4]|new[6]	_	_
3-8	65-73	includes	_	_	_	_
3-9	74-81	several	abstract[7]	new[7]	_	_
3-10	82-97	arthropod-borne	abstract[7]	new[7]	_	_
3-11	98-103	human	abstract[7]	new[7]	_	_
3-12	104-113	pathogens	abstract[7]	new[7]	_	_
3-13	114-118	that	_	_	_	_
3-14	119-122	may	_	_	_	_
3-15	123-128	cause	_	_	_	_
3-16	129-130	a	abstract[8]	new[8]	_	_
3-17	131-139	spectrum	abstract[8]	new[8]	_	_
3-18	140-142	of	abstract[8]	new[8]	_	_
3-19	143-151	clinical	abstract[8]|abstract[9]	new[8]|new[9]	coref	13-16[100_9]
3-20	152-161	syndromes	abstract[8]|abstract[9]	new[8]|new[9]	_	_
3-21	162-169	ranging	_	_	_	_
3-22	170-174	from	_	_	_	_
3-23	175-176	a	abstract[11]	new[11]	coref	5-9[38_11]
3-24	177-181	mild	abstract[11]	new[11]	_	_
3-25	182-189	febrile	object|abstract[11]	new|new[11]	coref	7-13
3-26	190-197	illness	abstract[11]	new[11]	_	_
3-27	198-200	to	abstract[11]	new[11]	_	_
3-28	201-207	severe	abstract[11]|abstract[13]	new[11]|new[13]	coref	12-34[0_13]
3-29	208-219	hemorrhagic	abstract[11]|place|abstract[13]	new[11]|new|new[13]	coref	12-45
3-30	220-225	fever	abstract[11]|abstract[13]	new[11]|new[13]	_	_
3-31	226-228	or	abstract[11]	new[11]	_	_
3-32	229-242	neuroinvasive	abstract[11]|abstract[14]	new[11]|new[14]	coref	5-13[39_14]
3-33	243-250	disease	abstract[11]|abstract[14]	new[11]|new[14]	_	_
3-34	251-252	.	_	_	_	_

#Text=Neurotropic flaviviruses , such as West Nile virus ( WNV ) , Japanese encephalitis virus ( JEV ) , and tick-borne encephalitis virus ( TBEV ) , are maintained in nature in transmission cycles involving mosquito ( mainly Culex spp. ) or tick ( mainly Ixodes spp. ) vectors and mammalian or bird amplification hosts , with humans serving as dead-end incidental hosts .
4-1	253-264	Neurotropic	abstract|object[16]	new|new[16]	coref|coref|coref|coref	7-2[50_16]|12-6|7-2[50_16]|12-6
4-2	265-277	flaviviruses	object[16]	new[16]	_	_
4-3	278-279	,	object[16]	new[16]	_	_
4-4	280-284	such	object[16]	new[16]	_	_
4-5	285-287	as	object[16]	new[16]	_	_
4-6	288-292	West	object[16]|place[17]|abstract[18]	new[16]|new[17]|new[18]	appos|appos	4-10[0_18]|4-10[0_18]
4-7	293-297	Nile	object[16]|place[17]|abstract[18]	new[16]|new[17]|new[18]	_	_
4-8	298-303	virus	object[16]|abstract[18]	new[16]|new[18]	_	_
4-9	304-305	(	_	_	_	_
4-10	306-309	WNV	abstract	giv	coref	22-39
4-11	310-311	)	_	_	_	_
4-12	312-313	,	_	_	_	_
4-13	314-322	Japanese	abstract[21]	new[21]	appos	4-17[0_21]
4-14	323-335	encephalitis	abstract|abstract[21]	new|new[21]	coref	4-22
4-15	336-341	virus	abstract[21]	new[21]	_	_
4-16	342-343	(	_	_	_	_
4-17	344-347	JEV	abstract	giv	_	_
4-18	348-349	)	_	_	_	_
4-19	350-351	,	_	_	_	_
4-20	352-355	and	_	_	_	_
4-21	356-366	tick-borne	abstract[24]	new[24]	appos	4-25[0_24]
4-22	367-379	encephalitis	abstract|abstract[24]	giv|new[24]	_	_
4-23	380-385	virus	abstract[24]	new[24]	_	_
4-24	386-387	(	_	_	_	_
4-25	388-392	TBEV	abstract	giv	coref	6-1[44_0]
4-26	393-394	)	_	_	_	_
4-27	395-396	,	_	_	_	_
4-28	397-400	are	_	_	_	_
4-29	401-411	maintained	_	_	_	_
4-30	412-414	in	_	_	_	_
4-31	415-421	nature	abstract[26]	new[26]	_	_
4-32	422-424	in	abstract[26]	new[26]	_	_
4-33	425-437	transmission	abstract[26]|abstract|abstract[28]	new[26]|new|new[28]	_	_
4-34	438-444	cycles	abstract[26]|abstract[28]	new[26]|new[28]	_	_
4-35	445-454	involving	_	_	_	_
4-36	455-463	mosquito	animal	new	_	_
4-37	464-465	(	_	_	_	_
4-38	466-472	mainly	_	_	_	_
4-39	473-478	Culex	_	_	_	_
4-40	479-483	spp.	_	_	_	_
4-41	484-485	)	_	_	_	_
4-42	486-488	or	_	_	_	_
4-43	489-493	tick	person	new	_	_
4-44	494-495	(	_	_	_	_
4-45	496-502	mainly	_	_	_	_
4-46	503-509	Ixodes	person	new	_	_
4-47	510-514	spp.	_	_	_	_
4-48	515-516	)	_	_	_	_
4-49	517-524	vectors	person	new	_	_
4-50	525-528	and	_	_	_	_
4-51	529-538	mammalian	person	new	_	_
4-52	539-541	or	_	_	_	_
4-53	542-546	bird	animal|person[35]	new|new[35]	_	_
4-54	547-560	amplification	person[35]	new[35]	_	_
4-55	561-566	hosts	person[35]	new[35]	_	_
4-56	567-568	,	_	_	_	_
4-57	569-573	with	_	_	_	_
4-58	574-580	humans	person	new	coref	10-5[70_0]
4-59	581-588	serving	_	_	_	_
4-60	589-591	as	_	_	_	_
4-61	592-600	dead-end	_	_	_	_
4-62	601-611	incidental	_	_	_	_
4-63	612-617	hosts	_	_	_	_
4-64	618-619	.	_	_	_	_

#Text=Most human infections are asymptomatic or characterized by flu-like illness , while a severe and potentially fatal neuroinvasive disease occurs in a minority of cases , mostly immunocompromised and elderly individuals .
5-1	620-624	Most	abstract[37]	new[37]	coref	7-8[52_37]
5-2	625-630	human	abstract[37]	new[37]	_	_
5-3	631-641	infections	abstract[37]	new[37]	_	_
5-4	642-645	are	_	_	_	_
5-5	646-658	asymptomatic	_	_	_	_
5-6	659-661	or	_	_	_	_
5-7	662-675	characterized	_	_	_	_
5-8	676-678	by	_	_	_	_
5-9	679-687	flu-like	abstract[38]	giv[38]	coref	7-11[54_38]
5-10	688-695	illness	abstract[38]	giv[38]	_	_
5-11	696-697	,	_	_	_	_
5-12	698-703	while	_	_	_	_
5-13	704-705	a	abstract[39]	giv[39]	coref	12-45[94_39]
5-14	706-712	severe	abstract[39]	giv[39]	_	_
5-15	713-716	and	abstract[39]	giv[39]	_	_
5-16	717-728	potentially	abstract[39]	giv[39]	_	_
5-17	729-734	fatal	abstract[39]	giv[39]	_	_
5-18	735-748	neuroinvasive	abstract[39]	giv[39]	_	_
5-19	749-756	disease	abstract[39]	giv[39]	_	_
5-20	757-763	occurs	_	_	_	_
5-21	764-766	in	_	_	_	_
5-22	767-768	a	quantity[40]	new[40]	_	_
5-23	769-777	minority	quantity[40]	new[40]	_	_
5-24	778-780	of	quantity[40]	new[40]	_	_
5-25	781-786	cases	quantity[40]|abstract	new[40]|new	coref	12-16[84_0]
5-26	787-788	,	_	_	_	_
5-27	789-795	mostly	_	_	_	_
5-28	796-813	immunocompromised	_	_	_	_
5-29	814-817	and	_	_	_	_
5-30	818-825	elderly	_	_	_	_
5-31	826-837	individuals	person	new	coref	9-14[68_0]
5-32	838-839	.	_	_	_	_

#Text=Zika virus ( ZIKV ) has recently drawn attention due to the large outbreaks that occurred in Pacific Ocean countries and the Americas .
6-1	840-844	Zika	object|abstract[44]	new|giv[44]	appos|coref|appos|coref	6-4[0_44]|8-22|6-4[0_44]|8-22
6-2	845-850	virus	abstract[44]	giv[44]	_	_
6-3	851-852	(	_	_	_	_
6-4	853-857	ZIKV	abstract	giv	coref	7-5
6-5	858-859	)	_	_	_	_
6-6	860-863	has	_	_	_	_
6-7	864-872	recently	_	_	_	_
6-8	873-878	drawn	_	_	_	_
6-9	879-888	attention	abstract	new	_	_
6-10	889-892	due	_	_	_	_
6-11	893-895	to	_	_	_	_
6-12	896-899	the	event[47]	new[47]	_	_
6-13	900-905	large	event[47]	new[47]	_	_
6-14	906-915	outbreaks	event[47]	new[47]	_	_
6-15	916-920	that	_	_	_	_
6-16	921-929	occurred	_	_	_	_
6-17	930-932	in	_	_	_	_
6-18	933-940	Pacific	place[48]	new[48]	_	_
6-19	941-946	Ocean	place[48]	new[48]	_	_
6-20	947-956	countries	place[48]	new[48]	_	_
6-21	957-960	and	_	_	_	_
6-22	961-964	the	place[49]	new[49]	_	_
6-23	965-973	Americas	place[49]	new[49]	_	_
6-24	974-975	.	_	_	_	_

#Text=Like other flaviviruses , ZIKV generally causes asymptomatic infections or a mild febrile illness .
7-1	976-980	Like	_	_	_	_
7-2	981-986	other	object[50]	giv[50]	coref	11-3[0_50]
7-3	987-999	flaviviruses	object[50]	giv[50]	_	_
7-4	1000-1001	,	_	_	_	_
7-5	1002-1006	ZIKV	object	giv	coref	8-23
7-6	1007-1016	generally	_	_	_	_
7-7	1017-1023	causes	_	_	_	_
7-8	1024-1036	asymptomatic	abstract[52]	giv[52]	coref	13-21[101_52]
7-9	1037-1047	infections	abstract[52]	giv[52]	_	_
7-10	1048-1050	or	abstract[52]	giv[52]	_	_
7-11	1051-1052	a	abstract[52]|abstract[54]	giv[52]|giv[54]	_	_
7-12	1053-1057	mild	abstract[52]|abstract[54]	giv[52]|giv[54]	_	_
7-13	1058-1065	febrile	abstract[52]|object|abstract[54]	giv[52]|giv|giv[54]	_	_
7-14	1066-1073	illness	abstract[52]|abstract[54]	giv[52]|giv[54]	_	_
7-15	1074-1075	.	_	_	_	_

#Text=Infection during pregnancy , especially during the first trimester , causes fetal microcephaly and other developmental anomalies , defined as congenital Zika virus syndrome .
8-1	1076-1085	Infection	abstract[55]	new[55]	coref	9-11[67_55]
8-2	1086-1092	during	abstract[55]	new[55]	_	_
8-3	1093-1102	pregnancy	abstract[55]|event	new[55]|new	_	_
8-4	1103-1104	,	_	_	_	_
8-5	1105-1115	especially	abstract[57]	new[57]	_	_
8-6	1116-1122	during	abstract[57]	new[57]	_	_
8-7	1123-1126	the	abstract[57]	new[57]	_	_
8-8	1127-1132	first	abstract[57]	new[57]	_	_
8-9	1133-1142	trimester	abstract[57]	new[57]	_	_
8-10	1143-1144	,	_	_	_	_
8-11	1145-1151	causes	_	_	_	_
8-12	1152-1157	fetal	_	_	_	_
8-13	1158-1170	microcephaly	_	_	_	_
8-14	1171-1174	and	_	_	_	_
8-15	1175-1180	other	abstract[58]	new[58]	_	_
8-16	1181-1194	developmental	abstract[58]	new[58]	_	_
8-17	1195-1204	anomalies	abstract[58]	new[58]	_	_
8-18	1205-1206	,	_	_	_	_
8-19	1207-1214	defined	_	_	_	_
8-20	1215-1217	as	_	_	_	_
8-21	1218-1228	congenital	_	_	_	_
8-22	1229-1233	Zika	place	giv	_	_
8-23	1234-1239	virus	abstract	giv	coref	9-11
8-24	1240-1248	syndrome	_	_	_	_
8-25	1249-1250	.	_	_	_	_

#Text=Guillain – Barré syndrome and meningoencephalitis are rare complications of ZIKV infection in adult individuals .
9-1	1251-1259	Guillain	person	new	_	_
9-2	1260-1261	–	_	_	_	_
9-3	1262-1267	Barré	person|abstract[63]	new|new[63]	_	_
9-4	1268-1276	syndrome	abstract[63]	new[63]	_	_
9-5	1277-1280	and	_	_	_	_
9-6	1281-1300	meningoencephalitis	abstract	new	coref	9-8[65_0]
9-7	1301-1304	are	_	_	_	_
9-8	1305-1309	rare	abstract[65]	giv[65]	coref	12-19[85_65]
9-9	1310-1323	complications	abstract[65]	giv[65]	_	_
9-10	1324-1326	of	abstract[65]	giv[65]	_	_
9-11	1327-1331	ZIKV	abstract[65]|object|abstract[67]	giv[65]|giv|giv[67]	coref|coref|coref|coref	10-1|13-32[0_67]|10-1|13-32[0_67]
9-12	1332-1341	infection	abstract[65]|abstract[67]	giv[65]|giv[67]	_	_
9-13	1342-1344	in	abstract[65]|abstract[67]	giv[65]|giv[67]	_	_
9-14	1345-1350	adult	abstract[65]|abstract[67]|person[68]	giv[65]|giv[67]|giv[68]	_	_
9-15	1351-1362	individuals	abstract[65]|abstract[67]|person[68]	giv[65]|giv[67]|giv[68]	_	_
9-16	1363-1364	.	_	_	_	_

#Text=ZIKV is transmitted between humans through the bite of infected Ae . aegypti and other Aedes species mosquitoes , with humans serving as amplifying hosts .
10-1	1365-1369	ZIKV	object	giv	coref	11-5
10-2	1370-1372	is	_	_	_	_
10-3	1373-1384	transmitted	_	_	_	_
10-4	1385-1392	between	_	_	_	_
10-5	1393-1399	humans	person[70]	giv[70]	coref	10-21[0_70]
10-6	1400-1407	through	person[70]	giv[70]	_	_
10-7	1408-1411	the	person[70]|abstract[71]	giv[70]|new[71]	_	_
10-8	1412-1416	bite	person[70]|abstract[71]	giv[70]|new[71]	_	_
10-9	1417-1419	of	person[70]|abstract[71]	giv[70]|new[71]	_	_
10-10	1420-1428	infected	person[70]|abstract[71]|person[72]	giv[70]|new[71]|new[72]	_	_
10-11	1429-1431	Ae	person[70]|abstract[71]|person[72]	giv[70]|new[71]|new[72]	_	_
10-12	1432-1433	.	person[70]|abstract[71]	giv[70]|new[71]	_	_
10-13	1434-1441	aegypti	person[70]|abstract[71]	giv[70]|new[71]	_	_
10-14	1442-1445	and	person[70]|abstract[71]	giv[70]|new[71]	_	_
10-15	1446-1451	other	person[70]|abstract[71]|animal[75]	giv[70]|new[71]|new[75]	_	_
10-16	1452-1457	Aedes	person[70]|abstract[71]|animal|animal[75]	giv[70]|new[71]|new|new[75]	_	_
10-17	1458-1465	species	person[70]|abstract[71]|animal|animal[75]	giv[70]|new[71]|new|new[75]	_	_
10-18	1466-1476	mosquitoes	person[70]|abstract[71]|animal[75]	giv[70]|new[71]|new[75]	_	_
10-19	1477-1478	,	_	_	_	_
10-20	1479-1483	with	_	_	_	_
10-21	1484-1490	humans	person	giv	coref	27-31
10-22	1491-1498	serving	_	_	_	_
10-23	1499-1501	as	_	_	_	_
10-24	1502-1512	amplifying	_	_	_	_
10-25	1513-1518	hosts	_	_	_	_
10-26	1519-1520	.	_	_	_	_

#Text=Unique among flaviviruses , ZIKV can persist in immune-privileged sites like the testis and be sexually transmitted .
11-1	1521-1527	Unique	_	_	_	_
11-2	1528-1533	among	_	_	_	_
11-3	1534-1546	flaviviruses	object	giv	coref	12-4[82_0]
11-4	1547-1548	,	_	_	_	_
11-5	1549-1553	ZIKV	object	giv	coref	12-27[88_0]
11-6	1554-1557	can	_	_	_	_
11-7	1558-1565	persist	_	_	_	_
11-8	1566-1568	in	_	_	_	_
11-9	1569-1586	immune-privileged	place[79]	new[79]	_	_
11-10	1587-1592	sites	place[79]	new[79]	_	_
11-11	1593-1597	like	place[79]	new[79]	_	_
11-12	1598-1601	the	place[79]|object[80]	new[79]|new[80]	_	_
11-13	1602-1608	testis	place[79]|object[80]	new[79]|new[80]	_	_
11-14	1609-1612	and	_	_	_	_
11-15	1613-1615	be	_	_	_	_
11-16	1616-1624	sexually	_	_	_	_
11-17	1625-1636	transmitted	_	_	_	_
11-18	1637-1638	.	_	_	_	_

#Text=In addition to these well-known neurotropic flaviviruses , there has been an increasing number of reported cases of neurological complications caused by viruses , such as dengue virus ( DENV ) and yellow fever virus ( YFV ) , which usually are associated with hemorrhagic disease .
12-1	1639-1641	In	_	_	_	_
12-2	1642-1650	addition	_	_	_	_
12-3	1651-1653	to	_	_	_	_
12-4	1654-1659	these	object[82]	giv[82]	coref	22-3[225_82]
12-5	1660-1670	well-known	object[82]	giv[82]	_	_
12-6	1671-1682	neurotropic	abstract|object[82]	giv|giv[82]	coref	22-36
12-7	1683-1695	flaviviruses	object[82]	giv[82]	_	_
12-8	1696-1697	,	_	_	_	_
12-9	1698-1703	there	_	_	_	_
12-10	1704-1707	has	_	_	_	_
12-11	1708-1712	been	_	_	_	_
12-12	1713-1715	an	abstract[83]	new[83]	_	_
12-13	1716-1726	increasing	abstract[83]	new[83]	_	_
12-14	1727-1733	number	abstract[83]	new[83]	_	_
12-15	1734-1736	of	abstract[83]	new[83]	_	_
12-16	1737-1745	reported	abstract[83]|abstract[84]	new[83]|giv[84]	_	_
12-17	1746-1751	cases	abstract[83]|abstract[84]	new[83]|giv[84]	_	_
12-18	1752-1754	of	abstract[83]|abstract[84]	new[83]|giv[84]	_	_
12-19	1755-1767	neurological	abstract[83]|abstract[84]|abstract[85]	new[83]|giv[84]|giv[85]	_	_
12-20	1768-1781	complications	abstract[83]|abstract[84]|abstract[85]	new[83]|giv[84]|giv[85]	_	_
12-21	1782-1788	caused	_	_	_	_
12-22	1789-1791	by	_	_	_	_
12-23	1792-1799	viruses	object[86]	new[86]	coref	21-7[0_86]
12-24	1800-1801	,	object[86]	new[86]	_	_
12-25	1802-1806	such	object[86]	new[86]	_	_
12-26	1807-1809	as	object[86]	new[86]	_	_
12-27	1810-1816	dengue	object[86]|object|abstract[88]	new[86]|new|giv[88]	appos|appos	12-30[0_88]|12-30[0_88]
12-28	1817-1822	virus	object[86]|abstract[88]	new[86]|giv[88]	_	_
12-29	1823-1824	(	_	_	_	_
12-30	1825-1829	DENV	abstract	giv	coref	12-33[91_0]
12-31	1830-1831	)	_	_	_	_
12-32	1832-1835	and	_	_	_	_
12-33	1836-1842	yellow	abstract[91]	giv[91]	appos	12-37[0_91]
12-34	1843-1848	fever	abstract|abstract[91]	giv|giv[91]	_	_
12-35	1849-1854	virus	abstract[91]	giv[91]	_	_
12-36	1855-1856	(	_	_	_	_
12-37	1857-1860	YFV	abstract	giv	coref	14-12
12-38	1861-1862	)	_	_	_	_
12-39	1863-1864	,	_	_	_	_
12-40	1865-1870	which	_	_	_	_
12-41	1871-1878	usually	_	_	_	_
12-42	1879-1882	are	_	_	_	_
12-43	1883-1893	associated	_	_	_	_
12-44	1894-1898	with	_	_	_	_
12-45	1899-1910	hemorrhagic	place|abstract[94]	giv|giv[94]	coref|coref	27-28[0_94]|27-28[0_94]
12-46	1911-1918	disease	abstract[94]	giv[94]	_	_
12-47	1919-1920	.	_	_	_	_

#Text=One of the central questions in the search for therapeutic targets for the treatment of flaviviral neurological syndromes is whether these diseases are induced by virus-mediated cytolysis , immune-pathological responses to infection , or a combination of both .
13-1	1921-1924	One	abstract[95]	new[95]	_	_
13-2	1925-1927	of	abstract[95]	new[95]	_	_
13-3	1928-1931	the	abstract[95]|abstract[96]	new[95]|new[96]	_	_
13-4	1932-1939	central	abstract[95]|abstract[96]	new[95]|new[96]	_	_
13-5	1940-1949	questions	abstract[95]|abstract[96]	new[95]|new[96]	_	_
13-6	1950-1952	in	abstract[95]|abstract[96]	new[95]|new[96]	_	_
13-7	1953-1956	the	abstract[95]|abstract[96]|event[97]	new[95]|new[96]|new[97]	_	_
13-8	1957-1963	search	abstract[95]|abstract[96]|event[97]	new[95]|new[96]|new[97]	_	_
13-9	1964-1967	for	abstract[95]|abstract[96]|event[97]	new[95]|new[96]|new[97]	_	_
13-10	1968-1979	therapeutic	abstract[95]|abstract[96]|event[97]|abstract[98]	new[95]|new[96]|new[97]|new[98]	coref	17-32[168_98]
13-11	1980-1987	targets	abstract[95]|abstract[96]|event[97]|abstract[98]	new[95]|new[96]|new[97]|new[98]	_	_
13-12	1988-1991	for	abstract[95]|abstract[96]|event[97]|abstract[98]	new[95]|new[96]|new[97]|new[98]	_	_
13-13	1992-1995	the	abstract[95]|abstract[96]|event[97]|abstract[98]|abstract[99]	new[95]|new[96]|new[97]|new[98]|new[99]	_	_
13-14	1996-2005	treatment	abstract[95]|abstract[96]|event[97]|abstract[98]|abstract[99]	new[95]|new[96]|new[97]|new[98]|new[99]	_	_
13-15	2006-2008	of	abstract[95]|abstract[96]|event[97]|abstract[98]|abstract[99]	new[95]|new[96]|new[97]|new[98]|new[99]	_	_
13-16	2009-2019	flaviviral	abstract[95]|abstract[96]|event[97]|abstract[98]|abstract[99]|abstract[100]	new[95]|new[96]|new[97]|new[98]|new[99]|giv[100]	_	_
13-17	2020-2032	neurological	abstract[95]|abstract[96]|event[97]|abstract[98]|abstract[99]|abstract[100]	new[95]|new[96]|new[97]|new[98]|new[99]|giv[100]	_	_
13-18	2033-2042	syndromes	abstract[95]|abstract[96]|event[97]|abstract[98]|abstract[99]|abstract[100]	new[95]|new[96]|new[97]|new[98]|new[99]|giv[100]	_	_
13-19	2043-2045	is	_	_	_	_
13-20	2046-2053	whether	_	_	_	_
13-21	2054-2059	these	abstract[101]	giv[101]	coref	14-45[122_101]
13-22	2060-2068	diseases	abstract[101]	giv[101]	_	_
13-23	2069-2072	are	_	_	_	_
13-24	2073-2080	induced	_	_	_	_
13-25	2081-2083	by	_	_	_	_
13-26	2084-2098	virus-mediated	abstract[102]	new[102]	_	_
13-27	2099-2108	cytolysis	abstract[102]	new[102]	_	_
13-28	2109-2110	,	_	_	_	_
13-29	2111-2130	immune-pathological	abstract[103]	new[103]	coref	14-38[121_103]
13-30	2131-2140	responses	abstract[103]	new[103]	_	_
13-31	2141-2143	to	abstract[103]	new[103]	_	_
13-32	2144-2153	infection	abstract[103]|abstract	new[103]|giv	coref	14-12[111_0]
13-33	2154-2155	,	_	_	_	_
13-34	2156-2158	or	_	_	_	_
13-35	2159-2160	a	abstract[105]	new[105]	_	_
13-36	2161-2172	combination	abstract[105]	new[105]	_	_
13-37	2173-2175	of	abstract[105]	new[105]	_	_
13-38	2176-2180	both	abstract[105]	new[105]	_	_
13-39	2181-2182	.	_	_	_	_

#Text=Animal models have permitted temporal analysis of the progressive dissemination of virus infection within the CNS and identification of cells targeted by viral infection , have revealed important details regarding host factors that restrict viral replication and the innate and adaptive immune responses to viral infections , and have been fundamental for vaccine development .
14-1	2183-2189	Animal	person|abstract[107]	new|new[107]	coref|coref	16-29[148_107]|16-29[148_107]
14-2	2190-2196	models	abstract[107]	new[107]	_	_
14-3	2197-2201	have	_	_	_	_
14-4	2202-2211	permitted	_	_	_	_
14-5	2212-2220	temporal	abstract[108]	new[108]	_	_
14-6	2221-2229	analysis	abstract[108]	new[108]	_	_
14-7	2230-2232	of	abstract[108]	new[108]	_	_
14-8	2233-2236	the	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-9	2237-2248	progressive	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-10	2249-2262	dissemination	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-11	2263-2265	of	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-12	2266-2271	virus	abstract[108]|abstract[109]|abstract|abstract[111]	new[108]|new[109]|giv|giv[111]	coref|coref|coref|coref	14-23[115_111]|17-17|14-23[115_111]|17-17
14-13	2272-2281	infection	abstract[108]|abstract[109]|abstract[111]	new[108]|new[109]|giv[111]	_	_
14-14	2282-2288	within	abstract[108]|abstract[109]|abstract[111]	new[108]|new[109]|giv[111]	_	_
14-15	2289-2292	the	abstract[108]|abstract[109]|abstract[111]|place[112]	new[108]|new[109]|giv[111]|new[112]	_	_
14-16	2293-2296	CNS	abstract[108]|abstract[109]|abstract[111]|place[112]	new[108]|new[109]|giv[111]|new[112]	_	_
14-17	2297-2300	and	abstract[108]|abstract[109]|abstract[111]	new[108]|new[109]|giv[111]	_	_
14-18	2301-2315	identification	abstract[108]|abstract[109]|abstract[111]|abstract[113]	new[108]|new[109]|giv[111]|new[113]	_	_
14-19	2316-2318	of	abstract[108]|abstract[109]|abstract[111]|abstract[113]	new[108]|new[109]|giv[111]|new[113]	_	_
14-20	2319-2324	cells	abstract[108]|abstract[109]|abstract[111]|abstract[113]|object	new[108]|new[109]|giv[111]|new[113]|new	coref	15-8[130_0]
14-21	2325-2333	targeted	_	_	_	_
14-22	2334-2336	by	_	_	_	_
14-23	2337-2342	viral	abstract[115]	giv[115]	coref	17-19[166_115]
14-24	2343-2352	infection	abstract[115]	giv[115]	_	_
14-25	2353-2354	,	_	_	_	_
14-26	2355-2359	have	_	_	_	_
14-27	2360-2368	revealed	_	_	_	_
14-28	2369-2378	important	abstract[116]	new[116]	_	_
14-29	2379-2386	details	abstract[116]	new[116]	_	_
14-30	2387-2396	regarding	_	_	_	_
14-31	2397-2401	host	abstract[117]	new[117]	_	_
14-32	2402-2409	factors	abstract[117]	new[117]	_	_
14-33	2410-2414	that	_	_	_	_
14-34	2415-2423	restrict	_	_	_	_
14-35	2424-2429	viral	abstract|abstract[119]	new|new[119]	coref|coref|coref|coref	21-30|23-13[0_119]|21-30|23-13[0_119]
14-36	2430-2441	replication	abstract[119]	new[119]	_	_
14-37	2442-2445	and	_	_	_	_
14-38	2446-2449	the	abstract[121]	giv[121]	coref	23-45[254_121]
14-39	2450-2456	innate	abstract[121]	giv[121]	_	_
14-40	2457-2460	and	abstract[121]	giv[121]	_	_
14-41	2461-2469	adaptive	abstract[121]	giv[121]	_	_
14-42	2470-2476	immune	abstract|abstract[121]	new|giv[121]	coref	20-5
14-43	2477-2486	responses	abstract[121]	giv[121]	_	_
14-44	2487-2489	to	abstract[121]	giv[121]	_	_
14-45	2490-2495	viral	abstract[121]|abstract[122]	giv[121]|giv[122]	coref	15-23[134_122]
14-46	2496-2506	infections	abstract[121]|abstract[122]	giv[121]|giv[122]	_	_
14-47	2507-2508	,	_	_	_	_
14-48	2509-2512	and	_	_	_	_
14-49	2513-2517	have	_	_	_	_
14-50	2518-2522	been	_	_	_	_
14-51	2523-2534	fundamental	_	_	_	_
14-52	2535-2538	for	_	_	_	_
14-53	2539-2546	vaccine	substance|abstract[124]	new|new[124]	coref|coref	16-59[158_124]|16-59[158_124]
14-54	2547-2558	development	abstract[124]	new[124]	_	_
14-55	2559-2560	.	_	_	_	_

#Text=Breakthroughs on cell reprogramming and generation of human induced pluripotent stem cells ( hiPSCs ) have revolutionized approaches to the study of human diseases . iPSCs are generated directly from adult differentiated cells that are reprogrammed back into an embryonic-like pluripotent state by introducing genes important for maintaining the essential properties of embryonic stem cells .
15-1	2561-2574	Breakthroughs	abstract[125]	new[125]	_	_
15-2	2575-2577	on	abstract[125]	new[125]	_	_
15-3	2578-2582	cell	abstract[125]|place|abstract[127]	new[125]|new|new[127]	coref|coref	18-29|18-29
15-4	2583-2596	reprogramming	abstract[125]|abstract[127]	new[125]|new[127]	_	_
15-5	2597-2600	and	abstract[125]	new[125]	_	_
15-6	2601-2611	generation	abstract[125]|abstract[128]	new[125]|new[128]	_	_
15-7	2612-2614	of	abstract[125]|abstract[128]	new[125]|new[128]	_	_
15-8	2615-2620	human	abstract[125]|abstract[128]|object[130]	new[125]|new[128]|giv[130]	appos	15-14[0_130]
15-9	2621-2628	induced	abstract[125]|abstract[128]|object[130]	new[125]|new[128]|giv[130]	_	_
15-10	2629-2640	pluripotent	abstract[125]|abstract[128]|object[130]	new[125]|new[128]|giv[130]	_	_
15-11	2641-2645	stem	abstract[125]|abstract[128]|plant|object[130]	new[125]|new[128]|new|giv[130]	coref	22-17
15-12	2646-2651	cells	abstract[125]|abstract[128]|object[130]	new[125]|new[128]|giv[130]	_	_
15-13	2652-2653	(	_	_	_	_
15-14	2654-2660	hiPSCs	object	giv	coref	15-31[136_0]
15-15	2661-2662	)	_	_	_	_
15-16	2663-2667	have	_	_	_	_
15-17	2668-2682	revolutionized	_	_	_	_
15-18	2683-2693	approaches	abstract[132]	new[132]	_	_
15-19	2694-2696	to	abstract[132]	new[132]	_	_
15-20	2697-2700	the	abstract[132]|abstract[133]	new[132]|new[133]	coref	23-2[237_133]
15-21	2701-2706	study	abstract[132]|abstract[133]	new[132]|new[133]	_	_
15-22	2707-2709	of	abstract[132]|abstract[133]	new[132]|new[133]	_	_
15-23	2710-2715	human	abstract[132]|abstract[133]|abstract[134]	new[132]|new[133]|giv[134]	coref	16-38[151_134]
15-24	2716-2724	diseases	abstract[132]|abstract[133]|abstract[134]	new[132]|new[133]|giv[134]	_	_
15-25	2725-2726	.	_	_	_	_
15-26	2727-2732	iPSCs	abstract	new	_	_
15-27	2733-2736	are	_	_	_	_
15-28	2737-2746	generated	_	_	_	_
15-29	2747-2755	directly	_	_	_	_
15-30	2756-2760	from	_	_	_	_
15-31	2761-2766	adult	object[136]	giv[136]	coref	15-53[141_136]
15-32	2767-2781	differentiated	object[136]	giv[136]	_	_
15-33	2782-2787	cells	object[136]	giv[136]	_	_
15-34	2788-2792	that	_	_	_	_
15-35	2793-2796	are	_	_	_	_
15-36	2797-2809	reprogrammed	_	_	_	_
15-37	2810-2814	back	_	_	_	_
15-38	2815-2819	into	_	_	_	_
15-39	2820-2822	an	abstract[138]	new[138]	_	_
15-40	2823-2837	embryonic-like	abstract[138]	new[138]	_	_
15-41	2838-2849	pluripotent	abstract|abstract[138]	new|new[138]	_	_
15-42	2850-2855	state	abstract[138]	new[138]	_	_
15-43	2856-2858	by	_	_	_	_
15-44	2859-2870	introducing	_	_	_	_
15-45	2871-2876	genes	abstract[139]	new[139]	coref	21-39[217_139]
15-46	2877-2886	important	abstract[139]	new[139]	_	_
15-47	2887-2890	for	_	_	_	_
15-48	2891-2902	maintaining	_	_	_	_
15-49	2903-2906	the	abstract[140]	new[140]	_	_
15-50	2907-2916	essential	abstract[140]	new[140]	_	_
15-51	2917-2927	properties	abstract[140]	new[140]	_	_
15-52	2928-2930	of	abstract[140]	new[140]	_	_
15-53	2931-2940	embryonic	abstract[140]|object[141]	new[140]|giv[141]	coref	16-3[143_141]
15-54	2941-2945	stem	abstract[140]|object[141]	new[140]|giv[141]	_	_
15-55	2946-2951	cells	abstract[140]|object[141]	new[140]|giv[141]	_	_
15-56	2952-2953	.	_	_	_	_

#Text=Generation of hiPSCs and their differentiation into a variety of cells and organoids have allow to set up versatile , non-invasive , ethically sustainable , cruelty-free , and patient-specific models for the investigation of the mechanisms of human diseases , including viral infections and host – pathogen interactions , for the discovery of new drugs , and for the development of personalized therapies .
16-1	2954-2964	Generation	abstract[142]	new[142]	_	_
16-2	2965-2967	of	abstract[142]	new[142]	_	_
16-3	2968-2974	hiPSCs	abstract[142]|object[143]	new[142]|giv[143]	coref	17-1[161_143]
16-4	2975-2978	and	abstract[142]|object[143]	new[142]|giv[143]	_	_
16-5	2979-2984	their	abstract[142]|object[143]|abstract[144]	new[142]|giv[143]|new[144]	coref	18-29[181_144]
16-6	2985-3000	differentiation	abstract[142]|object[143]|abstract[144]	new[142]|giv[143]|new[144]	_	_
16-7	3001-3005	into	abstract[142]|object[143]|abstract[144]	new[142]|giv[143]|new[144]	_	_
16-8	3006-3007	a	abstract[142]|object[143]|abstract[144]|object[145]	new[142]|giv[143]|new[144]|new[145]	_	_
16-9	3008-3015	variety	abstract[142]|object[143]|abstract[144]|object[145]	new[142]|giv[143]|new[144]|new[145]	_	_
16-10	3016-3018	of	abstract[142]|object[143]|abstract[144]|object[145]	new[142]|giv[143]|new[144]|new[145]	_	_
16-11	3019-3024	cells	abstract[142]|object[143]|abstract[144]|object[145]	new[142]|giv[143]|new[144]|new[145]	_	_
16-12	3025-3028	and	abstract[142]|object[143]|abstract[144]|object[145]	new[142]|giv[143]|new[144]|new[145]	_	_
16-13	3029-3038	organoids	abstract[142]|object[143]|abstract[144]|object[145]|abstract	new[142]|giv[143]|new[144]|new[145]|new	coref	17-6[162_0]
16-14	3039-3043	have	_	_	_	_
16-15	3044-3049	allow	_	_	_	_
16-16	3050-3052	to	_	_	_	_
16-17	3053-3056	set	_	_	_	_
16-18	3057-3059	up	_	_	_	_
16-19	3060-3069	versatile	_	_	_	_
16-20	3070-3071	,	_	_	_	_
16-21	3072-3084	non-invasive	_	_	_	_
16-22	3085-3086	,	_	_	_	_
16-23	3087-3096	ethically	_	_	_	_
16-24	3097-3108	sustainable	_	_	_	_
16-25	3109-3110	,	_	_	_	_
16-26	3111-3123	cruelty-free	abstract	new	_	_
16-27	3124-3125	,	_	_	_	_
16-28	3126-3129	and	_	_	_	_
16-29	3130-3146	patient-specific	abstract[148]	giv[148]	coref	27-6[284_148]
16-30	3147-3153	models	abstract[148]	giv[148]	_	_
16-31	3154-3157	for	abstract[148]	giv[148]	_	_
16-32	3158-3161	the	abstract[148]|abstract[149]	giv[148]|new[149]	coref	20-8[203_149]
16-33	3162-3175	investigation	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
16-34	3176-3178	of	abstract[148]|abstract[149]	giv[148]|new[149]	_	_
16-35	3179-3182	the	abstract[148]|abstract[149]|abstract[150]	giv[148]|new[149]|new[150]	_	_
16-36	3183-3193	mechanisms	abstract[148]|abstract[149]|abstract[150]	giv[148]|new[149]|new[150]	_	_
16-37	3194-3196	of	abstract[148]|abstract[149]|abstract[150]	giv[148]|new[149]|new[150]	_	_
16-38	3197-3202	human	abstract[148]|abstract[149]|abstract[150]|abstract[151]	giv[148]|new[149]|new[150]|giv[151]	coref	16-42[152_151]
16-39	3203-3211	diseases	abstract[148]|abstract[149]|abstract[150]|abstract[151]	giv[148]|new[149]|new[150]|giv[151]	_	_
16-40	3212-3213	,	abstract[148]|abstract[149]|abstract[150]	giv[148]|new[149]|new[150]	_	_
16-41	3214-3223	including	abstract[148]|abstract[149]|abstract[150]	giv[148]|new[149]|new[150]	_	_
16-42	3224-3229	viral	abstract[148]|abstract[149]|abstract[150]|abstract[152]	giv[148]|new[149]|new[150]|giv[152]	_	_
16-43	3230-3240	infections	abstract[148]|abstract[149]|abstract[150]|abstract[152]	giv[148]|new[149]|new[150]|giv[152]	_	_
16-44	3241-3244	and	abstract[148]|abstract[149]|abstract[150]|abstract[152]	giv[148]|new[149]|new[150]|giv[152]	_	_
16-45	3245-3249	host	abstract[148]|abstract[149]|abstract[150]|abstract[152]|person	giv[148]|new[149]|new[150]|giv[152]|new	coref	23-45
16-46	3250-3251	–	abstract[148]|abstract[149]|abstract[150]|abstract[152]	giv[148]|new[149]|new[150]|giv[152]	_	_
16-47	3252-3260	pathogen	abstract[148]|abstract[149]|abstract[150]|abstract[152]|abstract|abstract[155]	giv[148]|new[149]|new[150]|giv[152]|new|new[155]	_	_
16-48	3261-3273	interactions	abstract[148]|abstract[149]|abstract[150]|abstract[152]|abstract[155]	giv[148]|new[149]|new[150]|giv[152]|new[155]	_	_
16-49	3274-3275	,	abstract[148]|abstract[149]|abstract[150]|abstract[152]|abstract[155]	giv[148]|new[149]|new[150]|giv[152]|new[155]	_	_
16-50	3276-3279	for	abstract[148]|abstract[149]|abstract[150]|abstract[152]|abstract[155]	giv[148]|new[149]|new[150]|giv[152]|new[155]	_	_
16-51	3280-3283	the	abstract[148]|abstract[149]|abstract[150]|abstract[152]|abstract[155]|abstract[156]	giv[148]|new[149]|new[150]|giv[152]|new[155]|new[156]	_	_
16-52	3284-3293	discovery	abstract[148]|abstract[149]|abstract[150]|abstract[152]|abstract[155]|abstract[156]	giv[148]|new[149]|new[150]|giv[152]|new[155]|new[156]	_	_
16-53	3294-3296	of	abstract[148]|abstract[149]|abstract[150]|abstract[152]|abstract[155]|abstract[156]	giv[148]|new[149]|new[150]|giv[152]|new[155]|new[156]	_	_
16-54	3297-3300	new	abstract[148]|abstract[149]|abstract[150]|abstract[152]|abstract[155]|abstract[156]|object[157]	giv[148]|new[149]|new[150]|giv[152]|new[155]|new[156]|new[157]	_	_
16-55	3301-3306	drugs	abstract[148]|abstract[149]|abstract[150]|abstract[152]|abstract[155]|abstract[156]|object[157]	giv[148]|new[149]|new[150]|giv[152]|new[155]|new[156]|new[157]	_	_
16-56	3307-3308	,	_	_	_	_
16-57	3309-3312	and	_	_	_	_
16-58	3313-3316	for	_	_	_	_
16-59	3317-3320	the	abstract[158]	giv[158]	coref	19-11[191_158]
16-60	3321-3332	development	abstract[158]	giv[158]	_	_
16-61	3333-3335	of	abstract[158]	giv[158]	_	_
16-62	3336-3348	personalized	abstract[158]|abstract[159]	giv[158]|new[159]	_	_
16-63	3349-3358	therapies	abstract[158]|abstract[159]	giv[158]|new[159]	_	_
16-64	3359-3360	.	_	_	_	_

#Text=Human iPSC-derived neural cells and brain organoids have been extensively used to investigate the mechanisms of ZIKV and other flavivirus infection and pathogenesis and have been used as platforms to discover therapeutic targets and to test antiviral compounds .
17-1	3361-3366	Human	object[161]	giv[161]	coref	18-4[0_161]
17-2	3367-3379	iPSC-derived	substance|object[161]	new|giv[161]	coref	19-2
17-3	3380-3386	neural	object[161]	giv[161]	_	_
17-4	3387-3392	cells	object[161]	giv[161]	_	_
17-5	3393-3396	and	object[161]	giv[161]	_	_
17-6	3397-3402	brain	object[161]|abstract[162]	giv[161]|giv[162]	coref	19-1[188_162]
17-7	3403-3412	organoids	object[161]|abstract[162]	giv[161]|giv[162]	_	_
17-8	3413-3417	have	_	_	_	_
17-9	3418-3422	been	_	_	_	_
17-10	3423-3434	extensively	_	_	_	_
17-11	3435-3439	used	_	_	_	_
17-12	3440-3442	to	_	_	_	_
17-13	3443-3454	investigate	_	_	_	_
17-14	3455-3458	the	abstract[163]	new[163]	coref	20-10[204_163]
17-15	3459-3469	mechanisms	abstract[163]	new[163]	_	_
17-16	3470-3472	of	abstract[163]	new[163]	_	_
17-17	3473-3477	ZIKV	abstract[163]|abstract	new[163]|giv	coref	18-15[175_0]
17-18	3478-3481	and	abstract[163]	new[163]	_	_
17-19	3482-3487	other	abstract[163]|abstract[166]	new[163]|giv[166]	coref	18-26[179_166]
17-20	3488-3498	flavivirus	abstract[163]|object|abstract[166]	new[163]|giv|giv[166]	_	_
17-21	3499-3508	infection	abstract[163]|abstract[166]	new[163]|giv[166]	_	_
17-22	3509-3512	and	abstract[163]	new[163]	_	_
17-23	3513-3525	pathogenesis	abstract[163]|abstract	new[163]|new	_	_
17-24	3526-3529	and	_	_	_	_
17-25	3530-3534	have	_	_	_	_
17-26	3535-3539	been	_	_	_	_
17-27	3540-3544	used	_	_	_	_
17-28	3545-3547	as	_	_	_	_
17-29	3548-3557	platforms	_	_	_	_
17-30	3558-3560	to	_	_	_	_
17-31	3561-3569	discover	_	_	_	_
17-32	3570-3581	therapeutic	abstract[168]	giv[168]	_	_
17-33	3582-3589	targets	abstract[168]	giv[168]	_	_
17-34	3590-3593	and	_	_	_	_
17-35	3594-3596	to	_	_	_	_
17-36	3597-3601	test	_	_	_	_
17-37	3602-3611	antiviral	object[169]	new[169]	_	_
17-38	3612-3621	compounds	object[169]	new[169]	_	_
17-39	3622-3623	.	_	_	_	_

#Text=Initial studies with hiPSCs studies were crucial to provide evidence of the tropism of ZIKV for human cortical neural progenitor cells and to demonstrate that ZIKV infection impairs cell differentiation and induces apoptosis , supporting the causative role of ZIKV in fetal microcephaly .
18-1	3624-3631	Initial	abstract[170]	new[170]	_	_
18-2	3632-3639	studies	abstract[170]	new[170]	_	_
18-3	3640-3644	with	abstract[170]	new[170]	_	_
18-4	3645-3651	hiPSCs	abstract[170]|object|abstract[172]	new[170]|giv|new[172]	coref|coref	18-17[177_0]|18-17[177_0]
18-5	3652-3659	studies	abstract[170]|abstract[172]	new[170]|new[172]	_	_
18-6	3660-3664	were	_	_	_	_
18-7	3665-3672	crucial	_	_	_	_
18-8	3673-3675	to	_	_	_	_
18-9	3676-3683	provide	_	_	_	_
18-10	3684-3692	evidence	abstract[173]	new[173]	_	_
18-11	3693-3695	of	abstract[173]	new[173]	_	_
18-12	3696-3699	the	abstract[173]|abstract[174]	new[173]|new[174]	coref	22-13[228_174]
18-13	3700-3707	tropism	abstract[173]|abstract[174]	new[173]|new[174]	_	_
18-14	3708-3710	of	abstract[173]|abstract[174]	new[173]|new[174]	_	_
18-15	3711-3715	ZIKV	abstract[173]|abstract[174]|abstract[175]	new[173]|new[174]|giv[175]	coref	18-26[0_175]
18-16	3716-3719	for	abstract[173]|abstract[174]|abstract[175]	new[173]|new[174]|giv[175]	_	_
18-17	3720-3725	human	abstract[173]|abstract[174]|abstract[175]|object[177]	new[173]|new[174]|giv[175]|giv[177]	coref	19-23[195_177]
18-18	3726-3734	cortical	abstract[173]|abstract[174]|abstract[175]|object[177]	new[173]|new[174]|giv[175]|giv[177]	_	_
18-19	3735-3741	neural	abstract[173]|abstract[174]|abstract[175]|object[177]	new[173]|new[174]|giv[175]|giv[177]	_	_
18-20	3742-3752	progenitor	abstract[173]|abstract[174]|abstract[175]|object|object[177]	new[173]|new[174]|giv[175]|new|giv[177]	_	_
18-21	3753-3758	cells	abstract[173]|abstract[174]|abstract[175]|object[177]	new[173]|new[174]|giv[175]|giv[177]	_	_
18-22	3759-3762	and	_	_	_	_
18-23	3763-3765	to	_	_	_	_
18-24	3766-3777	demonstrate	_	_	_	_
18-25	3778-3782	that	_	_	_	_
18-26	3783-3787	ZIKV	object|abstract[179]	giv|giv[179]	coref|coref|coref|coref	18-40[184_0]|21-30[215_179]|18-40[184_0]|21-30[215_179]
18-27	3788-3797	infection	abstract[179]	giv[179]	_	_
18-28	3798-3805	impairs	_	_	_	_
18-29	3806-3810	cell	place|abstract[181]	giv|giv[181]	coref|coref|coref|coref	19-37|21-19[0_181]|19-37|21-19[0_181]
18-30	3811-3826	differentiation	abstract[181]	giv[181]	_	_
18-31	3827-3830	and	_	_	_	_
18-32	3831-3838	induces	_	_	_	_
18-33	3839-3848	apoptosis	event	new	_	_
18-34	3849-3850	,	_	_	_	_
18-35	3851-3861	supporting	_	_	_	_
18-36	3862-3865	the	abstract[183]	new[183]	_	_
18-37	3866-3875	causative	abstract[183]	new[183]	_	_
18-38	3876-3880	role	abstract[183]	new[183]	_	_
18-39	3881-3883	of	abstract[183]	new[183]	_	_
18-40	3884-3888	ZIKV	abstract[183]|abstract[184]	new[183]|giv[184]	coref	19-20[0_184]
18-41	3889-3891	in	abstract[183]|abstract[184]	new[183]|giv[184]	_	_
18-42	3892-3897	fetal	abstract[183]|abstract[184]|object[185]	new[183]|giv[184]|new[185]	_	_
18-43	3898-3910	microcephaly	abstract[183]|abstract[184]|object[185]	new[183]|giv[184]|new[185]	_	_
18-44	3911-3912	.	_	_	_	_

#Text=Human iPSC-derived brain organoids , which are 3D structures mimicking endogenous human brain development and organization , showed that ZIKV preferentially infects radial glia cells as compared to intermediate progenitors or immature neurons , leading to cell death .
19-1	3913-3918	Human	abstract[188]	giv[188]	_	_
19-2	3919-3931	iPSC-derived	abstract|abstract[188]	giv|giv[188]	_	_
19-3	3932-3937	brain	object|abstract[188]	new|giv[188]	coref	19-13
19-4	3938-3947	organoids	abstract[188]	giv[188]	_	_
19-5	3948-3949	,	_	_	_	_
19-6	3950-3955	which	_	_	_	_
19-7	3956-3959	are	_	_	_	_
19-8	3960-3962	3D	object[189]	new[189]	_	_
19-9	3963-3973	structures	object[189]	new[189]	_	_
19-10	3974-3983	mimicking	_	_	_	_
19-11	3984-3994	endogenous	abstract[191]	giv[191]	_	_
19-12	3995-4000	human	abstract[191]	giv[191]	_	_
19-13	4001-4006	brain	object|abstract[191]	giv|giv[191]	_	_
19-14	4007-4018	development	abstract[191]	giv[191]	_	_
19-15	4019-4022	and	_	_	_	_
19-16	4023-4035	organization	abstract	new	_	_
19-17	4036-4037	,	_	_	_	_
19-18	4038-4044	showed	_	_	_	_
19-19	4045-4049	that	_	_	_	_
19-20	4050-4054	ZIKV	abstract	giv	coref	20-13
19-21	4055-4069	preferentially	_	_	_	_
19-22	4070-4077	infects	_	_	_	_
19-23	4078-4084	radial	object[195]	giv[195]	coref	21-23[213_195]
19-24	4085-4089	glia	place|object[195]	new|giv[195]	_	_
19-25	4090-4095	cells	object[195]	giv[195]	_	_
19-26	4096-4098	as	_	_	_	_
19-27	4099-4107	compared	_	_	_	_
19-28	4108-4110	to	_	_	_	_
19-29	4111-4123	intermediate	object[196]	new[196]	_	_
19-30	4124-4135	progenitors	object[196]	new[196]	_	_
19-31	4136-4138	or	_	_	_	_
19-32	4139-4147	immature	object[197]	new[197]	coref	23-35[250_197]
19-33	4148-4155	neurons	object[197]	new[197]	_	_
19-34	4156-4157	,	_	_	_	_
19-35	4158-4165	leading	_	_	_	_
19-36	4166-4168	to	_	_	_	_
19-37	4169-4173	cell	object|event[199]	giv|new[199]	coref|coref|coref|coref	21-18|25-28[272_199]|21-18|25-28[272_199]
19-38	4174-4179	death	event[199]	new[199]	_	_
19-39	4180-4181	.	_	_	_	_

#Text=Activation of TLR3-mediated innate immune response was one of the mechanisms involved ZIKV deleterious effects on neurogenesis .
20-1	4182-4192	Activation	event[200]	new[200]	_	_
20-2	4193-4195	of	event[200]	new[200]	_	_
20-3	4196-4209	TLR3-mediated	event[200]|abstract[202]	new[200]|new[202]	coref	26-23[279_202]
20-4	4210-4216	innate	event[200]|abstract[202]	new[200]|new[202]	_	_
20-5	4217-4223	immune	event[200]|abstract|abstract[202]	new[200]|giv|new[202]	coref	26-23
20-6	4224-4232	response	event[200]|abstract[202]	new[200]|new[202]	_	_
20-7	4233-4236	was	_	_	_	_
20-8	4237-4240	one	abstract[203]	giv[203]	_	_
20-9	4241-4243	of	abstract[203]	giv[203]	_	_
20-10	4244-4247	the	abstract[203]|abstract[204]	giv[203]|giv[204]	coref	27-14[286_204]
20-11	4248-4258	mechanisms	abstract[203]|abstract[204]	giv[203]|giv[204]	_	_
20-12	4259-4267	involved	_	_	_	_
20-13	4268-4272	ZIKV	abstract|abstract[206]	giv|new[206]	coref|coref	22-9|22-9
20-14	4273-4284	deleterious	abstract[206]	new[206]	_	_
20-15	4285-4292	effects	abstract[206]	new[206]	_	_
20-16	4293-4295	on	abstract[206]	new[206]	_	_
20-17	4296-4308	neurogenesis	abstract[206]|abstract	new[206]|new	_	_
20-18	4309-4310	.	_	_	_	_

#Text=In addition , the ability of viruses to infect and replicate was found to be dependent on cell differentiation status , since stem cells appear to be refractory to viral infection probably due to constitutive high-level expression of interferon-stimulated genes ( ISGs ) , while cell susceptibility to viral infection increases in differentiated cells .
21-1	4311-4313	In	_	_	_	_
21-2	4314-4322	addition	_	_	_	_
21-3	4323-4324	,	_	_	_	_
21-4	4325-4328	the	abstract[208]	new[208]	_	_
21-5	4329-4336	ability	abstract[208]	new[208]	_	_
21-6	4337-4339	of	abstract[208]	new[208]	_	_
21-7	4340-4347	viruses	abstract[208]|object	new[208]|giv	_	_
21-8	4348-4350	to	_	_	_	_
21-9	4351-4357	infect	_	_	_	_
21-10	4358-4361	and	_	_	_	_
21-11	4362-4371	replicate	_	_	_	_
21-12	4372-4375	was	_	_	_	_
21-13	4376-4381	found	_	_	_	_
21-14	4382-4384	to	_	_	_	_
21-15	4385-4387	be	_	_	_	_
21-16	4388-4397	dependent	_	_	_	_
21-17	4398-4400	on	_	_	_	_
21-18	4401-4405	cell	place|abstract[212]	giv|new[212]	coref|coref	21-46|21-46
21-19	4406-4421	differentiation	abstract|abstract[212]	giv|new[212]	coref	24-16[261_0]
21-20	4422-4428	status	abstract[212]	new[212]	_	_
21-21	4429-4430	,	_	_	_	_
21-22	4431-4436	since	_	_	_	_
21-23	4437-4441	stem	object[213]	giv[213]	coref	21-53[223_213]
21-24	4442-4447	cells	object[213]	giv[213]	_	_
21-25	4448-4454	appear	_	_	_	_
21-26	4455-4457	to	_	_	_	_
21-27	4458-4460	be	_	_	_	_
21-28	4461-4471	refractory	_	_	_	_
21-29	4472-4474	to	_	_	_	_
21-30	4475-4480	viral	object|abstract[215]	giv|giv[215]	coref|coref|coref|coref	21-49|21-49[222_215]|21-49|21-49[222_215]
21-31	4481-4490	infection	abstract[215]	giv[215]	_	_
21-32	4491-4499	probably	_	_	_	_
21-33	4500-4503	due	_	_	_	_
21-34	4504-4506	to	_	_	_	_
21-35	4507-4519	constitutive	abstract[216]	new[216]	coref	26-21[281_216]
21-36	4520-4530	high-level	abstract[216]	new[216]	_	_
21-37	4531-4541	expression	abstract[216]	new[216]	_	_
21-38	4542-4544	of	abstract[216]	new[216]	_	_
21-39	4545-4566	interferon-stimulated	abstract[216]|abstract[217]	new[216]|giv[217]	_	_
21-40	4567-4572	genes	abstract[216]|abstract[217]	new[216]|giv[217]	_	_
21-41	4573-4574	(	_	_	_	_
21-42	4575-4579	ISGs	event	new	_	_
21-43	4580-4581	)	_	_	_	_
21-44	4582-4583	,	_	_	_	_
21-45	4584-4589	while	_	_	_	_
21-46	4590-4594	cell	place|event[220]	giv|new[220]	coref|coref	24-17|24-17
21-47	4595-4609	susceptibility	event[220]	new[220]	_	_
21-48	4610-4612	to	event[220]	new[220]	_	_
21-49	4613-4618	viral	event[220]|object|abstract[222]	new[220]|giv|giv[222]	coref|coref	23-42[252_222]|23-42[252_222]
21-50	4619-4628	infection	event[220]|abstract[222]	new[220]|giv[222]	_	_
21-51	4629-4638	increases	_	_	_	_
21-52	4639-4641	in	_	_	_	_
21-53	4642-4656	differentiated	object[223]	giv[223]	coref	22-16[230_223]
21-54	4657-4662	cells	object[223]	giv[223]	_	_
21-55	4663-4664	.	_	_	_	_

#Text=Comparisons with other flaviviruses — e. g. , DENV — showed that the tropism for neural stem cells was a distinguishing feature of ZIKV , but no extensive comparative analyses have been performed with typically neurotropic flaviviruses like WNV .
22-1	4665-4676	Comparisons	abstract[224]	new[224]	_	_
22-2	4677-4681	with	abstract[224]	new[224]	_	_
22-3	4682-4687	other	abstract[224]|abstract[225]	new[224]|giv[225]	appos	22-6[226_225]
22-4	4688-4700	flaviviruses	abstract[224]|abstract[225]	new[224]|giv[225]	_	_
22-5	4701-4702	—	_	_	_	_
22-6	4703-4705	e.	abstract[226]	giv[226]	coref	22-35[235_226]
22-7	4706-4708	g.	abstract[226]	giv[226]	_	_
22-8	4709-4710	,	abstract[226]	giv[226]	_	_
22-9	4711-4715	DENV	abstract[226]|abstract	giv[226]|giv	coref	22-24
22-10	4716-4717	—	_	_	_	_
22-11	4718-4724	showed	_	_	_	_
22-12	4725-4729	that	_	_	_	_
22-13	4730-4733	the	abstract[228]	giv[228]	coref	22-20[231_228]
22-14	4734-4741	tropism	abstract[228]	giv[228]	_	_
22-15	4742-4745	for	abstract[228]	giv[228]	_	_
22-16	4746-4752	neural	abstract[228]|object[230]	giv[228]|giv[230]	coref	23-25[0_230]
22-17	4753-4757	stem	abstract[228]|plant|object[230]	giv[228]|giv|giv[230]	coref	23-29
22-18	4758-4763	cells	abstract[228]|object[230]	giv[228]|giv[230]	_	_
22-19	4764-4767	was	_	_	_	_
22-20	4768-4769	a	abstract[231]	giv[231]	coref	23-10[0_231]
22-21	4770-4784	distinguishing	abstract[231]	giv[231]	_	_
22-22	4785-4792	feature	abstract[231]	giv[231]	_	_
22-23	4793-4795	of	abstract[231]	giv[231]	_	_
22-24	4796-4800	ZIKV	abstract[231]|abstract	giv[231]|giv	coref	23-16
22-25	4801-4802	,	_	_	_	_
22-26	4803-4806	but	_	_	_	_
22-27	4807-4809	no	abstract[233]	new[233]	_	_
22-28	4810-4819	extensive	abstract[233]	new[233]	_	_
22-29	4820-4831	comparative	abstract[233]	new[233]	_	_
22-30	4832-4840	analyses	abstract[233]	new[233]	_	_
22-31	4841-4845	have	_	_	_	_
22-32	4846-4850	been	_	_	_	_
22-33	4851-4860	performed	_	_	_	_
22-34	4861-4865	with	_	_	_	_
22-35	4866-4875	typically	object[235]	giv[235]	coref	26-6[274_235]
22-36	4876-4887	neurotropic	abstract|object[235]	giv|giv[235]	_	_
22-37	4888-4900	flaviviruses	object[235]	giv[235]	_	_
22-38	4901-4905	like	object[235]	giv[235]	_	_
22-39	4906-4909	WNV	object[235]|abstract	giv[235]|giv	coref	23-21
22-40	4910-4911	.	_	_	_	_

#Text=In this study , we investigated the infectivity , tropism , and replication kinetics of ZIKV , in comparison with WNV and DENV in hiPSCs , hiPSCs-derived neural stem cells ( NSCs ) and undifferentiated neurons , and the effect of viral infection on host innate antiviral responses .
23-1	4912-4914	In	_	_	_	_
23-2	4915-4919	this	abstract[237]	giv[237]	coref	25-4[264_237]
23-3	4920-4925	study	abstract[237]	giv[237]	_	_
23-4	4926-4927	,	_	_	_	_
23-5	4928-4930	we	person	acc	ana	24-4
23-6	4931-4943	investigated	_	_	_	_
23-7	4944-4947	the	abstract[239]	new[239]	_	_
23-8	4948-4959	infectivity	abstract[239]	new[239]	_	_
23-9	4960-4961	,	_	_	_	_
23-10	4962-4969	tropism	abstract	giv	_	_
23-11	4970-4971	,	_	_	_	_
23-12	4972-4975	and	_	_	_	_
23-13	4976-4987	replication	abstract|abstract[242]	giv|new[242]	_	_
23-14	4988-4996	kinetics	abstract[242]	new[242]	_	_
23-15	4997-4999	of	abstract[242]	new[242]	_	_
23-16	5000-5004	ZIKV	abstract[242]|abstract	new[242]|giv	coref	23-23[246_0]
23-17	5005-5006	,	abstract[242]	new[242]	_	_
23-18	5007-5009	in	abstract[242]	new[242]	_	_
23-19	5010-5020	comparison	abstract[242]|abstract[244]	new[242]|new[244]	_	_
23-20	5021-5025	with	abstract[242]|abstract[244]	new[242]|new[244]	_	_
23-21	5026-5029	WNV	abstract[242]|abstract[244]|abstract	new[242]|new[244]|giv	coref	25-17
23-22	5030-5033	and	abstract[242]|abstract[244]	new[242]|new[244]	_	_
23-23	5034-5038	DENV	abstract[242]|abstract[244]|abstract[246]	new[242]|new[244]|giv[246]	coref	24-9[0_246]
23-24	5039-5041	in	abstract[242]|abstract[244]|abstract[246]	new[242]|new[244]|giv[246]	_	_
23-25	5042-5048	hiPSCs	abstract[242]|abstract[244]|abstract[246]|object	new[242]|new[244]|giv[246]|giv	coref	23-27[249_0]
23-26	5049-5050	,	_	_	_	_
23-27	5051-5065	hiPSCs-derived	object[249]	giv[249]	coref	24-6[0_249]
23-28	5066-5072	neural	object[249]	giv[249]	_	_
23-29	5073-5077	stem	plant|object[249]	giv|giv[249]	_	_
23-30	5078-5083	cells	object[249]	giv[249]	_	_
23-31	5084-5085	(	object[249]	giv[249]	_	_
23-32	5086-5090	NSCs	object[249]	giv[249]	_	_
23-33	5091-5092	)	object[249]	giv[249]	_	_
23-34	5093-5096	and	_	_	_	_
23-35	5097-5113	undifferentiated	object[250]	giv[250]	coref	26-15[0_250]
23-36	5114-5121	neurons	object[250]	giv[250]	_	_
23-37	5122-5123	,	_	_	_	_
23-38	5124-5127	and	_	_	_	_
23-39	5128-5131	the	abstract[251]	new[251]	_	_
23-40	5132-5138	effect	abstract[251]	new[251]	_	_
23-41	5139-5141	of	abstract[251]	new[251]	_	_
23-42	5142-5147	viral	abstract[251]|abstract[252]	new[251]|giv[252]	coref	24-9[258_252]
23-43	5148-5157	infection	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
23-44	5158-5160	on	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
23-45	5161-5165	host	abstract[251]|abstract[252]|person|abstract[254]	new[251]|giv[252]|giv|giv[254]	_	_
23-46	5166-5172	innate	abstract[251]|abstract[252]|abstract[254]	new[251]|giv[252]|giv[254]	_	_
23-47	5173-5182	antiviral	abstract[251]|abstract[252]|abstract[254]	new[251]|giv[252]|giv[254]	_	_
23-48	5183-5192	responses	abstract[251]|abstract[252]|abstract[254]	new[251]|giv[252]|giv[254]	_	_
23-49	5193-5194	.	_	_	_	_

#Text=In addition , we exploited hiPSCs to model ZIKV infection in the embryo and during stem cell differentiation towards the neuronal lineage .
24-1	5195-5197	In	_	_	_	_
24-2	5198-5206	addition	_	_	_	_
24-3	5207-5208	,	_	_	_	_
24-4	5209-5211	we	person	giv	_	_
24-5	5212-5221	exploited	_	_	_	_
24-6	5222-5228	hiPSCs	object	giv	coref	25-20[269_0]
24-7	5229-5231	to	_	_	_	_
24-8	5232-5237	model	_	_	_	_
24-9	5238-5242	ZIKV	object|abstract[258]	giv|giv[258]	coref|coref|coref|coref	25-10|27-7[0_258]|25-10|27-7[0_258]
24-10	5243-5252	infection	abstract[258]	giv[258]	_	_
24-11	5253-5255	in	abstract[258]	giv[258]	_	_
24-12	5256-5259	the	abstract[258]|place[259]	giv[258]|new[259]	_	_
24-13	5260-5266	embryo	abstract[258]|place[259]	giv[258]|new[259]	_	_
24-14	5267-5270	and	_	_	_	_
24-15	5271-5277	during	_	_	_	_
24-16	5278-5282	stem	abstract[261]	giv[261]	_	_
24-17	5283-5287	cell	place|abstract[261]	giv|giv[261]	coref	25-29
24-18	5288-5303	differentiation	abstract[261]	giv[261]	_	_
24-19	5304-5311	towards	abstract[261]	giv[261]	_	_
24-20	5312-5315	the	abstract[261]|abstract[262]	giv[261]|new[262]	_	_
24-21	5316-5324	neuronal	abstract[261]|abstract[262]	giv[261]|new[262]	_	_
24-22	5325-5332	lineage	abstract[261]|abstract[262]	giv[261]|new[262]	_	_
24-23	5333-5334	.	_	_	_	_

#Text=The results of this study confirmed the tropism of ZIKV for NSCs , but showed that WNV replicated in these cells with much higher efficiency , inducing massive cell death .
25-1	5335-5338	The	abstract[263]	new[263]	_	_
25-2	5339-5346	results	abstract[263]	new[263]	_	_
25-3	5347-5349	of	abstract[263]	new[263]	_	_
25-4	5350-5354	this	abstract[263]|abstract[264]	new[263]|giv[264]	_	_
25-5	5355-5360	study	abstract[263]|abstract[264]	new[263]|giv[264]	_	_
25-6	5361-5370	confirmed	_	_	_	_
25-7	5371-5374	the	abstract[265]	new[265]	coref	27-19[287_265]
25-8	5375-5382	tropism	abstract[265]	new[265]	_	_
25-9	5383-5385	of	abstract[265]	new[265]	_	_
25-10	5386-5390	ZIKV	abstract[265]|abstract	new[265]|giv	_	_
25-11	5391-5394	for	_	_	_	_
25-12	5395-5399	NSCs	organization	new	_	_
25-13	5400-5401	,	_	_	_	_
25-14	5402-5405	but	_	_	_	_
25-15	5406-5412	showed	_	_	_	_
25-16	5413-5417	that	_	_	_	_
25-17	5418-5421	WNV	abstract	giv	_	_
25-18	5422-5432	replicated	_	_	_	_
25-19	5433-5435	in	_	_	_	_
25-20	5436-5441	these	object[269]	giv[269]	coref	26-11[275_269]
25-21	5442-5447	cells	object[269]	giv[269]	_	_
25-22	5448-5452	with	_	_	_	_
25-23	5453-5457	much	abstract[270]	new[270]	_	_
25-24	5458-5464	higher	abstract[270]	new[270]	_	_
25-25	5465-5475	efficiency	abstract[270]	new[270]	_	_
25-26	5476-5477	,	_	_	_	_
25-27	5478-5486	inducing	_	_	_	_
25-28	5487-5494	massive	event[272]	giv[272]	_	_
25-29	5495-5499	cell	place|event[272]	giv|giv[272]	_	_
25-30	5500-5505	death	event[272]	giv[272]	_	_
25-31	5506-5507	.	_	_	_	_

#Text=Although with lower efficiency , all flaviviruses could also infect pluripotent stem cells and neurons , inducing similar patterns of antiviral innate immune response gene expression .
26-1	5508-5516	Although	_	_	_	_
26-2	5517-5521	with	_	_	_	_
26-3	5522-5527	lower	abstract[273]	new[273]	_	_
26-4	5528-5538	efficiency	abstract[273]	new[273]	_	_
26-5	5539-5540	,	_	_	_	_
26-6	5541-5544	all	object[274]	giv[274]	_	_
26-7	5545-5557	flaviviruses	object[274]	giv[274]	_	_
26-8	5558-5563	could	_	_	_	_
26-9	5564-5568	also	_	_	_	_
26-10	5569-5575	infect	_	_	_	_
26-11	5576-5587	pluripotent	object[275]	giv[275]	_	_
26-12	5588-5592	stem	object[275]	giv[275]	_	_
26-13	5593-5598	cells	object[275]	giv[275]	_	_
26-14	5599-5602	and	object[275]	giv[275]	_	_
26-15	5603-5610	neurons	object[275]|object	giv[275]|giv	_	_
26-16	5611-5612	,	_	_	_	_
26-17	5613-5621	inducing	_	_	_	_
26-18	5622-5629	similar	abstract[277]	new[277]	_	_
26-19	5630-5638	patterns	abstract[277]	new[277]	_	_
26-20	5639-5641	of	abstract[277]	new[277]	_	_
26-21	5642-5651	antiviral	abstract[277]|abstract[281]	new[277]|giv[281]	_	_
26-22	5652-5658	innate	abstract[277]|abstract[281]	new[277]|giv[281]	_	_
26-23	5659-5665	immune	abstract[277]|abstract|abstract[279]|abstract[281]	new[277]|giv|giv[279]|giv[281]	_	_
26-24	5666-5674	response	abstract[277]|abstract[279]|abstract[281]	new[277]|giv[279]|giv[281]	_	_
26-25	5675-5679	gene	abstract[277]|abstract|abstract[281]	new[277]|new|giv[281]	_	_
26-26	5680-5690	expression	abstract[277]|abstract[281]	new[277]|giv[281]	_	_
26-27	5691-5692	.	_	_	_	_

#Text=While showing the usefulness of hiPSC-based infection models , these findings suggest that additional virus-specific mechanisms , beyond neural tropism , are responsible for the peculiarities of disease phenotype in humans .
27-1	5693-5698	While	_	_	_	_
27-2	5699-5706	showing	_	_	_	_
27-3	5707-5710	the	abstract[282]	new[282]	_	_
27-4	5711-5721	usefulness	abstract[282]	new[282]	_	_
27-5	5722-5724	of	abstract[282]	new[282]	_	_
27-6	5725-5736	hiPSC-based	abstract[282]|abstract[284]	new[282]|giv[284]	_	_
27-7	5737-5746	infection	abstract[282]|abstract|abstract[284]	new[282]|giv|giv[284]	_	_
27-8	5747-5753	models	abstract[282]|abstract[284]	new[282]|giv[284]	_	_
27-9	5754-5755	,	_	_	_	_
27-10	5756-5761	these	abstract[285]	new[285]	_	_
27-11	5762-5770	findings	abstract[285]	new[285]	_	_
27-12	5771-5778	suggest	_	_	_	_
27-13	5779-5783	that	_	_	_	_
27-14	5784-5794	additional	abstract[286]	giv[286]	_	_
27-15	5795-5809	virus-specific	abstract[286]	giv[286]	_	_
27-16	5810-5820	mechanisms	abstract[286]	giv[286]	_	_
27-17	5821-5822	,	abstract[286]	giv[286]	_	_
27-18	5823-5829	beyond	abstract[286]	giv[286]	_	_
27-19	5830-5836	neural	abstract[286]|abstract[287]	giv[286]|giv[287]	_	_
27-20	5837-5844	tropism	abstract[286]|abstract[287]	giv[286]|giv[287]	_	_
27-21	5845-5846	,	_	_	_	_
27-22	5847-5850	are	_	_	_	_
27-23	5851-5862	responsible	_	_	_	_
27-24	5863-5866	for	_	_	_	_
27-25	5867-5870	the	abstract[288]	new[288]	_	_
27-26	5871-5884	peculiarities	abstract[288]	new[288]	_	_
27-27	5885-5887	of	abstract[288]	new[288]	_	_
27-28	5888-5895	disease	abstract[288]|abstract|abstract[290]	new[288]|giv|new[290]	_	_
27-29	5896-5905	phenotype	abstract[288]|abstract[290]	new[288]|new[290]	_	_
27-30	5906-5908	in	abstract[288]|abstract[290]	new[288]|new[290]	_	_
27-31	5909-5915	humans	abstract[288]|abstract[290]|person	new[288]|new[290]|giv	_	_
27-32	5916-5917	.	_	_	_	_
